Trial - Another victory over drugmakers’ FDA preemption argument.
The Center for Constitutional Litigation (CCL) has achieved another victory against arguments that FDA labeling regulations preempt state failure-to-warn claims. (Kelly v. Wyeth, 2007 WL 1302589 (Mass. Super. Apr. 12, 2007) .)
Related Results
Metoclopramide and akathisia
Learning the ins and outs of I.V. therapy
Letters to the Editor
Washington insider: Update
Antinausea Drugs
The April ruling in Massachusetts was the first decision to reject a claim of preemption by a generic drug manufacturer after the adverse ruling in Colacicco v. Apotex, Inc. In that case, a Pennsylvania district court held that the FDA’s preemption pronouncements were entitled to judicial deference and that a failure-to-warn claim involving a generic …
Read the rest of this article with a Free Trial at HighBeam Research.
